Variable | HR, 95Â % CI | p value |
---|---|---|
Sex | 0.81 (0.43–1.55) | 0.534 |
(male vs. female) | ||
Age | 0.74 (0.39–1.41) | 0.342 |
(>54 years vs. ≤54 years) | ||
ECOG performance status | 3.24 (1.40–7.50) | 0.006 |
(0–1 vs. 2–3) | ||
No. of brain metastases | 1.41 (0.74–2.69) | 0.299 |
(1–4 vs. >4) | ||
Max size of brain lesions | 1.03 (0.67–1.76) | 0.763 |
(<1Â cm vs. >1Â cm) | ||
Location of brain lesions | 1.62 (0.98–2.73) | 0.267 |
(Brain stem mets vs. Non–brain stem mets) | ||
Other sites of metastatic disease | 3.89 (1.58–9.57) | 0.002 |
(No vs. Yes) | ||
EGFR mutation | 0.74 (0.39–1.40) | 0.351 |
(Exon 19 vs. Exon 21) | ||
First line systemic treatment | 2.43 (1.08–5.48) | 0.032 |
(TKI vs. Chemotherapy) | ||
Time of brain RT | 0.77 (0.50–1.19) | 0.246 |
(First line vs. Delayed vs. No RT) |